Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | PTGES | O14684 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | STAT1 | P42224 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | CD44 | P16070 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.35 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19914269 | 0.92 | L3MBTL1 (0.43) | L3MBTL1GAACHRNB2CHRNA4LMNA | |
| SCHEMBL19914276 | 0.88 | L3MBTL1 (0.46) | L3MBTL1GAACHRNB2CHRNA4LMNA | |
| SCHEMBL31486630 | 0.83 | L3MBTL1 (0.48) | L3MBTL1GAACHRNB2CHRNA4LMNA | |
| SCHEMBL862784 | 0.83 | L3MBTL1 (0.48) | L3MBTL1GAACHRNB2CHRNA4LMNA | |
| SCHEMBL6010846 | 0.81 | LMNA (0.38) | LMNAALDH1A1POLBPTGESSMN1; SMN2 | |
| SCHEMBL720889 | 0.81 | L3MBTL1 (0.41) | L3MBTL1GAACHRNB2CHRNA4LMNA | |
| SCHEMBL5857975 | 0.81 | GAA (0.41) | L3MBTL1GAACHRNB2CHRNA4LMNA | |
| SCHEMBL19914262 | 0.81 | L3MBTL1 (0.41) | L3MBTL1GAACHRNB2CHRNA4LMNA | |
| SCHEMBL30995441 | 0.81 | GAA (0.41) | L3MBTL1GAACHRNB2CHRNA4LMNA | |
| SCHEMBL2756560 | 0.80 | L3MBTL1 (0.53) | L3MBTL1GAACHRNB2CHRNA4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189830-B2 | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders | BIOELECTRON TECHNOLOGY CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| WO-2018037223-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2018-03-01 | — | — | WO | disclosed |
| US-20160024085-A1 | ALKYL-HETEROARYL SUBSTITUTED QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | PTC THERAPEUTICS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-8330039-B2 | Solar cell modules with poly(vinyl butyral) encapsulant comprising unsaturated heterocyclic compound | E I DU PONT DE NEMOURS AND COMPANY (US) | 2012-12-11 | — | — | US | disclosed |
| EP-2380208-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. du Pont de Nemours and Company (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010085664-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-29 | — | — | WO | disclosed |
| US-20100180947-A1 | SOLAR CELL MODULES WITH POLY(VINYL BUTYRAL) ENCAPSULANT COMPRISING UNSATURATED HETEROCYCLIC COMPOUND | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2010-07-22 | — | — | US | disclosed |
| US-20050209274-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABOTT LABORATORIES | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024085-A1 | ALKYL-HETEROARYL SUBSTITUTED QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISORDERS | NQO1, COQ8A, NDUFAB1 | L3MBTL1 789/4885GAA 271/4885CHRNB2 830/4885 |
| US-20050209274-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | L3MBTL1 2777/4885GAA 425/4885CHRNB2 333/4885 |
| US-10189830-B2 | Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders | NQO1, COQ8A, NDUFAB1 | L3MBTL1 789/4885GAA 271/4885CHRNB2 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.